Ngum Nancy, Ndomondo-Sigonda Margareth, Habonimana Rémy, Siyoi Fred, Irasabwa Clarisse, Ojukwu Julia, Apolinary Felchism, Okello Andrew, Ahmada Sabrina, Walker Stuart, Salek Sam
Department of Clinical and Pharmaceutical Sciences, School of Life and Medical Sciences, University of Hertfordshire, Hatfield, United Kingdom.
African Union Development Agency-New Partnership for Africa's Development, Johannesburg, South Africa.
Front Med (Lausanne). 2024 Sep 17;11:1438041. doi: 10.3389/fmed.2024.1438041. eCollection 2024.
Medicines regulatory harmonisation has been embraced by many national regulatory authorities (NRAs) to improve public health through faster availability of safe, high-quality, and effective medical products to patients and enhanced standardisation of technical guidelines and work sharing, leading to reduced cost to pharmaceutical companies. After ten years of implementing regulatory harmonisation by the East African Community Medicines Registration Harmonization (EAC-MRH) initiative, it is now imperative for participating NRAs to rely on each other to minimise duplication of use of limited resources. Major challenges in implementing reliance are the lack of clear registration processes and delays in the approval. The aim of this study was to compare review models, target timelines and data requirements used in assessing applications by EAC-MRH NRAs so as to align and propose strategies for improvement.
A validated questionnaire that standardises and captures review processes was completed by the head of the medicine's registration division in each of the seven EAC-MRH NRAs. A country report based on the completed questionnaire was developed for each NRA and validated by the heads of the respective authorities.
Most applications received by all countries were for generics except Kenya, which received a significant number of new active substance applications (55 and 53 in 2020 and 2021). Mean approval times for generics using full review varied, with Tanzania's time declining for the three years. Target timelines for full review for the five countries ranged between 180 calendar days (Tanzania) to the highest 330 days (Zanzibar). The three countries (Kenya, Rwanda and Uganda) utilising the verification review model had a target timeline of 90 days. All six authorities conducted abridged reviews and fast-track assessments through a priority review track. The common technical document format was mandatory for applications in all authorities. The target timeline for key milestones in the review process varied for each country with a few similarities.
The study has provided a baseline for review models, target timelines and data requirements utilised in assessing applications for registration by EAC-MRH NRAs. Implementing the recommendations from this study will enable the NRAs to align and improve their registration processes.
许多国家药品监管机构(NRAs)都采用了药品监管协调措施,以通过更快地为患者提供安全、高质量和有效的医疗产品来改善公众健康,并加强技术指南的标准化和工作共享,从而降低制药公司的成本。在东非共同体药品注册协调(EAC-MRH)倡议实施监管协调十年后,参与的国家药品监管机构现在必须相互依赖,以尽量减少对有限资源的重复使用。实施相互依赖的主要挑战是缺乏明确的注册流程和审批延迟。本研究的目的是比较EAC-MRH国家药品监管机构在评估申请时使用的审查模式、目标时间线和数据要求,以便进行调整并提出改进策略。
由七个EAC-MRH国家药品监管机构中每个机构的药品注册部门负责人完成一份经过验证的问卷,该问卷用于规范和记录审查流程。根据填写完成的问卷为每个国家药品监管机构编写一份国家报告,并由各自机构的负责人进行验证。
除肯尼亚外,所有国家收到的大多数申请都是仿制药申请,肯尼亚在2020年和2021年收到了大量新活性物质申请(分别为55份和53份)。采用全面审查的仿制药平均批准时间各不相同,坦桑尼亚的时间在三年中有所下降。五个国家全面审查的目标时间线从180个日历日(坦桑尼亚)到最长的330天(桑给巴尔)不等。采用核查审查模式的三个国家(肯尼亚、卢旺达和乌干达)的目标时间线为90天。所有六个机构都通过优先审查通道进行简化审查和快速评估。通用技术文档格式对所有机构的申请都是强制性的。审查过程中关键里程碑的目标时间线因每个国家而异,有一些相似之处。
该研究为EAC-MRH国家药品监管机构在评估注册申请时使用的审查模式、目标时间线和数据要求提供了一个基线。实施本研究的建议将使国家药品监管机构能够调整并改进其注册流程。